CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.
CD13
Differential diagnosis
Immunohistochemistry
Meningeal tumors
Meningiomas
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
13
11
2021
accepted:
17
02
2022
revised:
30
01
2022
pubmed:
26
2
2022
medline:
14
6
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Meningiomas are common tumors of the central nervous system. Although their histological diagnosis is usually straightforward, their differential diagnosis versus other tumors may be challenging at times. The objective of this study is to assess the diagnostic value of CD13 immunoexpression in the differential diagnosis between meningiomas and their morphological mimics. Immunohistochemical analysis for CD13, epithelial membrane antigen, SOX10, and STAT6 was carried out in a large cohort of primary meningeal tumors comprising 225 meningiomas, 15 schwannomas, and 20 solitary fibrous tumor/hemangiopericytomas. Within the meningioma group, the expression of CD13 and epithelial membrane antigen was distinguished in three categories using a semiquantitative score. Most of meningiomas expressed CD13 (94%) and epithelial membrane antigen (96%) while none of the schwannomas nor of the solitary fibrous tumor/hemangiopericytomas was positive for either the two markers. Diffuse positivity for CD13 and epithelial membrane antigen was more common in low-grade meningiomas than in anaplastic ones, which were also more often negative for such markers, especially for CD13 (32%). CD13 is a helpful immunohistochemical marker for the differential diagnosis of meningiomas and their mimics, achieving in combination with epithelial membrane antigen maximal sensitivity (100%) and showing statistically relevant difference of expression in comparison with both schwannomas (p < 0.0001) and solitary fibrous tumor/hemangiopericytomas (p < 0.0001). Furthermore, loss of CD13 expression could be related to outcome as it is associated with worrisome histological findings, mainly in the setting of anaplastic meningiomas.
Identifiants
pubmed: 35212813
doi: 10.1007/s00428-022-03304-9
pii: 10.1007/s00428-022-03304-9
pmc: PMC9184408
doi:
Substances chimiques
Mucin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1223-1230Informations de copyright
© 2022. The Author(s).
Références
Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57(6):1088–1095. https://doi.org/10.1227/01.neu.0000188281.91351.b9
doi: 10.1227/01.neu.0000188281.91351.b9
pubmed: 16331155
Perry A, Louis DN, Budka H et al (2016) Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC press, Lyon, France, pp 232–245
Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Bressenot AM, Gauchotte G (2017) Immunohistochemical approach to the differential diagnosis of meningiomas and their mimics. J Neuropathol Exp Neurol 76(4):289–298. https://doi.org/10.1093/jnen/nlx008
doi: 10.1093/jnen/nlx008
pubmed: 28340171
Wickström M, Larsson R, Nygren P, Gullbo J (2011) Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102(3):501–508. https://doi.org/10.1111/j.1349-7006.2010.01826.x
doi: 10.1111/j.1349-7006.2010.01826.x
pubmed: 21205077
Mawrin C et al (2010) Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC. Brain Pathol 20(1):200–210. https://doi.org/10.1111/j.1750-3639.2009.00267.x
doi: 10.1111/j.1750-3639.2009.00267.x
pubmed: 19236378
Barresi V, Caffo M, Branca G, Caltabiano R, Tuccari G (2012) Meningeal tumors histologically mimicking meningioma. Pathol Res Pract 208(10):567–577. https://doi.org/10.1016/j.prp.2012.07.002
doi: 10.1016/j.prp.2012.07.002
pubmed: 22885109
Ülgen E et al (2019) Meningiomas display a specific immunoexpression pattern in a rostrocaudal gradient: an analysis of 366 patients. World Neurosurg 123:e520–e535. https://doi.org/10.1016/j.wneu.2018.11.201
doi: 10.1016/j.wneu.2018.11.201
pubmed: 30503291
Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH (1996) Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Pathol 106(2):217–224. https://doi.org/10.1093/ajcp/106.2.217
doi: 10.1093/ajcp/106.2.217
pubmed: 8712177
Vuorinen V, Sallinen P, Haapasalo H, Visakorpi T, Kallio M, Jääskeläinen J (1996) Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices. Acta Neurochir (Wien) 138(12):1399–1408. https://doi.org/10.1007/BF01411118
doi: 10.1007/BF01411118
Fritchie KJ, Jin L, Rubin BP et al (2016) NAB2-STAT6 gene fusion in meningeal hemangiopericytoma and solitary fibrous tumor. J Neuropathol Exp Neurol 75(3):263–271. https://doi.org/10.1093/jnen/nlv026
doi: 10.1093/jnen/nlv026
pubmed: 26883114
Koelsche C, Schweizer L, Renner M et al (2014) Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology 65(5):613–622. https://doi.org/10.1111/his.12431
doi: 10.1111/his.12431
pubmed: 24702701
Macagno N, Figarella-Branger D, Mokthari K et al (2016) Differential diagnosis of meningeal SFT-HPC and meningioma: which immunohistochemical markers should be used? Am J Surg Pathol 40(2):270–278. https://doi.org/10.1097/PAS.0000000000000526
doi: 10.1097/PAS.0000000000000526
pubmed: 26448189
Schweizer L, Koelsche C, Sahm F et al (2013) Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125(5):651–658. https://doi.org/10.1007/s00401-013-1117-6
doi: 10.1007/s00401-013-1117-6
pubmed: 23575898
Agaimy A, Buslei R, Coras R, Rubin BP, Mentzel T (2014) Comparative study of soft tissue perineurioma and meningioma using a five-marker immunohistochemical panel. Histopathology 65(1):60–70. https://doi.org/10.1111/his.12366
doi: 10.1111/his.12366
pubmed: 24393170
Johnson MD, O’Connell MJ, Silberstein H, Korones D (2013) Differential expression of somatostatin receptors, P44/42 MAPK, and mTOR activation in medulloblastomas and primitive neuroectodermal tumors. Appl Immunohistochem Mol Morphol AIMM 21(6):532–538. https://doi.org/10.1097/PAI.0b013e3182813724
doi: 10.1097/PAI.0b013e3182813724
pubmed: 23455179
Dixon J, Kaklamanis L, Turley H et al (1994) Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 47(1):43–47. https://doi.org/10.1136/jcp.47.1.43
doi: 10.1136/jcp.47.1.43
pubmed: 7907609
pmcid: 501755
Martínez JM, Prieto I, Ramírez MJ, Cueva C, Alba F, Ramírez M (1999) Aminopeptidase activities in breast cancer tissue. Clin Chem 45(10):1797–1802
doi: 10.1093/clinchem/45.10.1797
Surowiak P, Drag M, Materna V et al (2006) “Expression of aminopeptidase N/CD13 in human ovarian cancers.” Int J Gynecol cancer Off J Int Gynecol Cancer Soc 16(5):1783–1788. https://doi.org/10.1111/j.1525-1438.2006.00657.x
doi: 10.1111/j.1525-1438.2006.00657.x
van Hensbergen Y, Broxterman H J, Rana S et al (2004) “Reduced growth increased vascular area and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts,.” Clin cancer Res an Off J Am Assoc Cancer Res 10(3):1180–1191. https://doi.org/10.1158/1078-0432.ccr-0482-3
doi: 10.1158/1078-0432.ccr-0482-3
Birkenkamp-Demtroder K, Christensen LL, Olesen SH et al (2002) Gene expression in colorectal cancer. Cancer Res 62(15):4352–4363
pubmed: 12154040
Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C (2003) Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 63(23):8500–8506
pubmed: 14679016
Severini G, Gentilini L, Tirelli C (1991) Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer. Cancer Biochem Biophys 12(3):199–204
pubmed: 1688253
Pasqualini R, Koivunen E, Kain R et al (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60(3):722–727
pubmed: 10676659
pmcid: 4469333
Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97(3):652–659. https://doi.org/10.1182/blood.v97.3.652
doi: 10.1182/blood.v97.3.652
pubmed: 11157481
Kido A, Krueger S, Haeckel C, Roessner A (2003) Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells. Clin Exp Metastasis 20(7):585–592. https://doi.org/10.1023/a:1027383729767
doi: 10.1023/a:1027383729767
pubmed: 14669789
pmcid: 7087608
Hashida H, Takabayashi A, Kanai M et al (2002) Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122(2):376–386. https://doi.org/10.1053/gast.2002.31095
doi: 10.1053/gast.2002.31095
pubmed: 11832452
Ranogajec I, Jakić-Razumović J, Puzović V, Gabrilovac J (2012) Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol 29(2):561–569. https://doi.org/10.1007/s12032-011-9984-y
doi: 10.1007/s12032-011-9984-y
pubmed: 21611838
Kawamura J, Shimada Y, Kitaichi H et al (2007) Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma. Hepatogastroenterology 54(73):36–40
pubmed: 17419227
Rempel SA, Ge S, Gutiérrez JA (1999) SPARC: a potential diagnostic marker of invasive meningiomas. Clin cancer Res an Off J Am Assoc Cancer Res 5(2):237–241
Zeltner L, Schittenhelm J, Mittelbronn M et al (2007) The astrocytic response towards invasive meningiomas. Neuropathol Appl Neurobiol 33(2):163–168. https://doi.org/10.1111/j.1365-2990.2006.00792.x
doi: 10.1111/j.1365-2990.2006.00792.x
pubmed: 17359357
Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T (2015) “Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen.” Acta neuropathologica 130(3):441–443. https://doi.org/10.1007/s00401-015-1459-3
doi: 10.1007/s00401-015-1459-3
pubmed: 26195322
H. Murakami, A. Yokoyama, K. Kondo, S. Nakanishi, N. Kohno, and M. Miyake, 2005 “Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer.,” Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res., vol. 11, no. 24 Pt 1, pp. 8674–8679 https://doi.org/10.1158/1078-0432.CCR-05-1005
Tokuhara T, Hattori N, Ishida H et al (2006) Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin cancer Res an Off J Am Assoc Cancer Res 12(13):3971–3978. https://doi.org/10.1158/1078-0432.CCR-06-0338
doi: 10.1158/1078-0432.CCR-06-0338
Ikeda N, Nakajima Y, Tokuhara T et al (2003) Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin cancer Res an Off J Am Assoc Cancer Res 9(4):1503–1508
Sanz B, Perez I, Beitia M et al (2015) Aminopeptidase N activity predicts 5-year survival in colorectal cancer patients. J Investig Med Off Publ Am Fed Clin Res 63(5):740–746. https://doi.org/10.1097/JIM.0000000000000199
doi: 10.1097/JIM.0000000000000199
Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A (2009) Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS 117(9):651–659. https://doi.org/10.1111/j.1600-0463.2009.02516.x
doi: 10.1111/j.1600-0463.2009.02516.x
pubmed: 19703125
Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A (2006) Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol 32(5):525–531. https://doi.org/10.1111/j.1365-2990.2006.00761.x
doi: 10.1111/j.1365-2990.2006.00761.x
pubmed: 16972886